Table.
Baseline Characteristics (n=245).
| Variable | Value |
|---|---|
| Demographics: | |
| Age (years) | 58 ± 13 |
| Male gender, n (%) | 164 (67%) |
| Body mass index (kg/m2) | 30 ± 6 |
| African American, n (%) | 45 (18%) |
| Heart failure history: | |
| Ischemic etiology, n (%) | 92 (39%) |
| NYHA class III or IV, n (%) | 95 (66%) |
| Co-morbidities: | |
| Hypertension, n (%) | 130 (54%) |
| Diabetes mellitus, n (%) | 92 (38%) |
| Echocardiographic indices: | |
| LV mass index (g/m2) | 159 ± 57 |
| LV end-diastolic volume index (mL/m2) | 97 ± 42 |
| LV ejection fraction (%) | 31 ± 13 |
| Mitral E/e’ ratio | 22 ± 12 |
| Mitral E/A ratio | 1.9 ± 1.0 |
| Mitral DT (ms) | 160 ± 52 |
| Tricuspid E/e’ ratio | 7.1 ± 3.8 |
| LA volume index (mL/m2) | 41 ± 17 |
| RV end-diastolic area (cm2) | 26 ± 9 |
| RV s’ (cm/s) | 9 ± 3 |
| RV Fractional area change | 34 ± 12 |
| Tricuspid DT (ms) | 189 ± 61 |
| RA volume index (mL/m2) | 34 ± 18 |
| Medications: | |
| Angiotensin converting enzyme inhibitors or angiotensin receptor blockers, n (%) |
143 (61%) |
| Beta-blockers, n (%) | 171 (73%) |
| Spironolactone, n (%) | 87 (37%) |
| Loop diuretics, n (%) | 151 (64%) |
| Digoxin, n (%) | 70 (30%) |
| Laboratory data: | |
| MBG (pM) | 583 [383, 812] |
| Myeloperoxidase (pM) | 124 [77- 253] |
| BNP (pg/mL) | 431 [97, 1417] |
| eGFR (mL/min/1.73m2) | 71 ± 32 |
| Cystatin C (mg/L) | 1.85 [1.31 – 2.61] |
| ADMA (μM) | 1.05 [0.82 – 1.33] |
| SDMA (μM) | 1.70 [1.05 – 2.96] |
| MMA (nM) | 50 [34 – 92] |
Abbreviation: NYHA, New York Heart Association; LV, left ventricular; RV, right ventricular; MBG, marinobufagenin (MBG); eGFR, estimated glomerular filtration rate; BNP, B-type natriuretic peptide, ADMA, Asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; MMA, mono methyl arginine.